期刊论文

Medication Rule of Traditional Chinese Medicine on Primary Hepatocellular Carcinoma with Ascites

中文

肿瘤防治研究

1000-8578

2019

46

10

901-904

10.3971/j.issn.1000-8578.2019.19.0271

国家自然科学基金青年科学基金(81503556) 国家中医临床研究基地业务建设科研专项课题(JDZX2015183) 国家自然科学基金(81704068)。

本校为第一机构

目的探讨原发性肝癌并腹水的中医临床用药规律及特点,以指导临床用药。方法收集186例原发性肝癌并腹水患者病例资料,建立临床中医用药数据库,对数据进行频数、关联规则等分析。结果186例患者其主证型从高到低依次为:肝血瘀阻证、肝血瘀阻证兼脾虚湿盛证、脾虚湿盛证、肝郁气滞兼肝血瘀阻证、气阴两虚证、湿毒蕴炽证,其中肝血瘀阻证临床总有效率最高。药物使用频率居于前15位的药物分别为:丹参、郁金、桃仁、穿山甲、红花、党参、黄芪、甘草、薏苡仁、茯苓、白花蛇舌草、半枝莲、柴胡、当归、鳖甲。结论原发性肝癌并腹水患者临床证型最常见为肝血瘀阻证,“活血祛瘀、利水渗湿、健脾理气、清热养阴...

Object To explore the clinical medication rule and feature of TCM on hepatocellular carcinoma with ascites. Methods We collected the clinical data of 186 hepatocellular carcinoma patients with ascites, established the clinical drugs database, and used frequency analysis and association rules to research the medication characteristics. Results In 186 patients, the proportion of TCM syndrome type from high to low in turn was liver blood stasis syndrome, liver blood stasis syndrome and spleen deficiency and dampness, spleen deficiency and dampness...